shutterstock_2169738405_t_schneider
T. Schneider / Shutterstock.com
21 July 2022AmericasStaff writer

Generic maker pays $145m to settle antitrust suit

California company resolves pay-for-delay issue over opioids | Allegations were brought by direct purchasers eight years ago.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More on this story

Big Pharma
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.

More on this story

Big Pharma
7 June 2021   Endo International and Amneal Pharmaceuticals’ subsidiary, Impax Laboratories, have failed to prevent antitrust claims over a patent settlement from going to trial.
Big Pharma
5 July 2022   The ruling marks the latest development of a long-running dispute over the alleged delay of a generic version of the blockbuster painkiller.